The most common genetic abnormality, present in 40–50% of prostate cancers [8], is the translocation of the transmembrane protease serine 2 to the v-ets erythroblastosis virus E26 oncogene (TMPRSS2-ETS) [9,10]. Here, TMPRSS2 is linked to prostate carcinoma.